Literature DB >> 8592994

Use of time-kill methodology to assess antimicrobial combinations against metronidazole-susceptible and metronidazole-resistant strains of Helicobacter pylori.

P E Coudron1, C W Stratton.   

Abstract

Optimal therapy for Helicobacter pylori infection to date, consists of metronidazole, bismuth, and tetracycline. This combination, however, is less effective against metronidazole-resistant organisms. We used a time-kill kinetic methodology to assess the bactericidal effects of selected agents, alone and in combination, to a metronidazole-susceptible and a metronidazole-resistant strain of H. pylori. single, double, and triple agents showed increasing bactericidal activity. The combination of metronidazole, bismuth, and tetracycline showed maximal killing effect (no detectable regrowth) against the susceptible strain, but against the resistant strain this combination showed less killing. The time-kill methodology may therefore offer an in vitro approach to the initial selection of agents to be evaluated for the treatment of H. pylori infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592994      PMCID: PMC163004          DOI: 10.1128/AAC.39.12.2641

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori.

Authors:  N Chiba; B V Rao; J W Rademaker; R H Hunt
Journal:  Am J Gastroenterol       Date:  1992-12       Impact factor: 10.864

Review 2.  Helicobacter pylori: its role in disease.

Authors:  M J Blaser
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

Review 3.  The who's and when's of therapy for Helicobacter pylori.

Authors:  D Y Graham; G M Börsch
Journal:  Am J Gastroenterol       Date:  1990-12       Impact factor: 10.864

4.  Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.

Authors:  D Y Graham; G M Lew; P D Klein; D G Evans; D J Evans; Z A Saeed; H M Malaty
Journal:  Ann Intern Med       Date:  1992-05-01       Impact factor: 25.391

5.  Comparison of rapid urease tests, staining techniques, and growth on different solid media for detection of Campylobacter pylori.

Authors:  P E Coudron; D F Kirby
Journal:  J Clin Microbiol       Date:  1989-07       Impact factor: 5.948

Review 6.  Drug therapy for Helicobacter pylori infection: problems and pitfalls.

Authors:  Y Glupczynski; A Burette
Journal:  Am J Gastroenterol       Date:  1990-12       Impact factor: 10.864

7.  In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).

Authors:  D L Van Caekenberghe; J Breyssens
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 8.  Treatment strategies for Helicobacter pylori infection.

Authors:  B J Marshall
Journal:  Gastroenterol Clin North Am       Date:  1993-03       Impact factor: 3.806

9.  Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth.

Authors:  D Y Graham; G M Lew; F C Ramirez; R M Genta; P D Klein; H M Malaty
Journal:  Aliment Pharmacol Ther       Date:  1993-02       Impact factor: 8.171

10.  Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.

Authors:  G D Bell; K Powell; S M Burridge; A Pallecaros; P H Jones; P W Gant; G Harrison; J E Trowell
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

View more
  6 in total

1.  In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Authors:  J K Akada; M Shirai; K Fujii; K Okita; T Nakazawa
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori.

Authors:  Margareta Svensson; Lennart E Nilsson; Magnus Ström; Maud Nilsson; Mikael Sörberg
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

3.  Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic.

Authors:  Stefanie Heller; Laurenz Kellenberger; Stuart Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

4.  In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.

Authors:  T Alarcón; D Domingo; I Sánchez; F Díaz de Rojas; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

Review 5.  Helicobacter pylori.

Authors:  B E Dunn; H Cohen; M J Blaser
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

6.  Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori.

Authors:  Ahmed Megahed Abouwarda; Tarek Abdelmonem Ismail; Wael Mohamed Abu El-Wafa; Ahmed Hassan Ibrahim Faraag
Journal:  World J Microbiol Biotechnol       Date:  2022-04-29       Impact factor: 4.253

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.